ErbituxCetuximab500 mgoneФл Colorectal Cancer (CRC) \r\n Erbitux is indicated for patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type (without mutation) metastatic colorectal cancer, strictly as determined by approved testing.
Erbitux is indicated for patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type (without mutation) metastatic colorectal cancer, strictly as determined by approved testing.
